Madrigal Pharmaceuticals provided an update on its financial performance, revealing preliminary fourth-quarter and full-year 2024 net sales for Rezdiffra™ (resmetirom) projected between $100 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback